Companies Sep 27, 2022 Thermo Fisher Gets FDA OK for CDx Test to Guide Use of Lilly Drug in Lung, Thyroid Cancers Sep 23, 2022 NICE Recommends Pfizer's Ibrance Combination for HER2-Negative Breast Cancer Sep 23, 2022 In Brief This Week: Seagen, Ideaya Biosciences, Cellistic, AstraZeneca, Kinnate Biopharma Sep 23, 2022 Caris Life Sciences to Offer Molecular Profiling Services on Flatiron Health Platform Sep 22, 2022 Universal Genetic Testing in Breast Cancer Further Supported in New Invitae-Led Study Sep 22, 2022 Persephone Biosciences Enrolls First Patient in Study of Microbiome Effect on Cancer Drug Response Sep 21, 2022 Merck KGaA, Nerviano Enter License Agreement for PARP1 Inhibitor NMS-293 Sep 21, 2022 Sophia Genetics Partners With MSK on Clinical Decision Support, Boundless Bio on ecDNA Detection Sep 21, 2022 Foundation Medicine, Day One Biopharmaceuticals to Develop CDx for Tovorafenib Sep 21, 2022 Tempus, Children's Oncology Group Expand Genomic Testing Access for Pediatric Cancer Patients Sep 20, 2022 Transcriptomics Plus 'Immune Tolerance' of Normal Tissue Shows Promise in Lung Cancer Prognosis Premium Sep 20, 2022 Gradalis' Autologous Immunotherapy Shows Promise in Certain Ovarian Cancer Patients Premium Sep 19, 2022 EMA's CHMP Recommends Gilead's Yescarta for Second-Line Lymphoma Sep 19, 2022 CancerRNA Consortium Will Harness RNA Technology to Enhance Immunotherapies Sep 16, 2022 BMS Combo Immunotherapy Opdualag Approved in Europe for Biomarker-Defined Melanoma Patients Sep 16, 2022 In Brief This Week:Â Precipio, AnHeart Therapeutics, Strata Oncology, Delfi Diagnostics, Incyte Sep 15, 2022 BriaCell, Caris Life Sciences Partner to Bolster New Immunotherapy Development Sep 13, 2022 Combination Trials Point to New Potential Treatment Strategies in Breast Cancer Premium Sep 13, 2022 ESMO Data Deepens Understanding of KRAS Inhibitor Activity in Lung, Colorectal Cancer Premium Sep 13, 2022 Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
